JP2024513048A - Rnaの送達のための組成物及び方法 - Google Patents
Rnaの送達のための組成物及び方法 Download PDFInfo
- Publication number
- JP2024513048A JP2024513048A JP2023560598A JP2023560598A JP2024513048A JP 2024513048 A JP2024513048 A JP 2024513048A JP 2023560598 A JP2023560598 A JP 2023560598A JP 2023560598 A JP2023560598 A JP 2023560598A JP 2024513048 A JP2024513048 A JP 2024513048A
- Authority
- JP
- Japan
- Prior art keywords
- tert
- lipid
- lnp
- composition
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169118P | 2021-03-31 | 2021-03-31 | |
| US63/169,118 | 2021-03-31 | ||
| PCT/US2022/022642 WO2022212576A1 (en) | 2021-03-31 | 2022-03-30 | Compositions and methods for delivery of rna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513048A true JP2024513048A (ja) | 2024-03-21 |
| JP2024513048A5 JP2024513048A5 (cg-RX-API-DMAC10.html) | 2025-04-01 |
Family
ID=83456716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560598A Pending JP2024513048A (ja) | 2021-03-31 | 2022-03-30 | Rnaの送達のための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220347112A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4312942A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024513048A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117396193A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022246851A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3215112A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL307319A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022212576A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117771213A (zh) * | 2023-01-10 | 2024-03-29 | 北京剂泰医药科技有限公司 | 脂质纳米颗粒组合物及其用途 |
| TW202509222A (zh) * | 2023-05-08 | 2025-03-01 | 美商默沙東有限責任公司 | 編碼諾羅病毒vp1抗原之多核苷酸及其用途 |
| WO2025049632A1 (en) * | 2023-08-29 | 2025-03-06 | Rejuvenation Technologies Inc. | Compositions and methods for broad delivery of rna to tissue |
| WO2025255027A1 (en) * | 2024-06-03 | 2025-12-11 | Flagship Labs 114, Inc. | Lipid nanoparticles for topical delivery |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026010842A1 (en) * | 2024-07-01 | 2026-01-08 | The Trustees Of The University Of Pennsylvania | Use of lipid nanoparticle mrna for tert specific cancer immunotherapy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019188867A1 (ja) * | 2018-03-27 | 2019-10-03 | 日油株式会社 | 細胞内動態を改善した新規カチオン性脂質 |
| WO2020051220A1 (en) * | 2018-09-04 | 2020-03-12 | The Board of the Regents of the University of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| US20200215094A1 (en) * | 2013-02-22 | 2020-07-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
| WO2020142725A1 (en) * | 2019-01-04 | 2020-07-09 | Oncorus, Inc. | Encapsulated rna polynucleotides and methods of use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL270631B2 (en) * | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
-
2022
- 2022-03-30 US US17/709,108 patent/US20220347112A1/en active Pending
- 2022-03-30 CN CN202280026001.6A patent/CN117396193A/zh active Pending
- 2022-03-30 CA CA3215112A patent/CA3215112A1/en active Pending
- 2022-03-30 EP EP22782138.6A patent/EP4312942A4/en active Pending
- 2022-03-30 WO PCT/US2022/022642 patent/WO2022212576A1/en not_active Ceased
- 2022-03-30 AU AU2022246851A patent/AU2022246851A1/en active Pending
- 2022-03-30 IL IL307319A patent/IL307319A/en unknown
- 2022-03-30 JP JP2023560598A patent/JP2024513048A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200215094A1 (en) * | 2013-02-22 | 2020-07-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, compositions, methods, and kits relating to telomere extension |
| WO2019188867A1 (ja) * | 2018-03-27 | 2019-10-03 | 日油株式会社 | 細胞内動態を改善した新規カチオン性脂質 |
| US20210023008A1 (en) * | 2018-03-27 | 2021-01-28 | Nof Corporation | Novel cationic lipid exhibiting improved intracellular dynamics |
| WO2020051220A1 (en) * | 2018-09-04 | 2020-03-12 | The Board of the Regents of the University of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| WO2020142725A1 (en) * | 2019-01-04 | 2020-07-09 | Oncorus, Inc. | Encapsulated rna polynucleotides and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3215112A1 (en) | 2022-10-06 |
| EP4312942A1 (en) | 2024-02-07 |
| WO2022212576A1 (en) | 2022-10-06 |
| AU2022246851A1 (en) | 2023-10-12 |
| CN117396193A (zh) | 2024-01-12 |
| AU2022246851A9 (en) | 2023-10-26 |
| EP4312942A4 (en) | 2025-03-19 |
| US20220347112A1 (en) | 2022-11-03 |
| IL307319A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12144895B2 (en) | Stabilized formulations of lipid nanoparticles | |
| US20220347112A1 (en) | Compositions and methods for delivery of rna | |
| EP3595727B1 (en) | Lipid nanoparticle formulation | |
| EP3852728B1 (en) | Preparation of lipid nanoparticles and methods of administration thereof | |
| EP3917503B1 (en) | Methods of preparing lipid nanoparticles | |
| US11744801B2 (en) | Methods of making lipid nanoparticles | |
| US12161709B2 (en) | Compositions for inducing an immune response against zika virus | |
| JP2022095702A (ja) | 脂質ナノ粒子の安定化製剤 | |
| JP2024501388A (ja) | Rnaの送達のための組成物および方法 | |
| HK40101750A (en) | Compositions and methods for delivery of rna | |
| JP2025529173A (ja) | Rna送達のための組成物及び方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231013 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231219 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250321 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250324 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260602 |